CN112972058A - 一种大脑出血模型鼠的建立和评价方法 - Google Patents
一种大脑出血模型鼠的建立和评价方法 Download PDFInfo
- Publication number
- CN112972058A CN112972058A CN202110254986.5A CN202110254986A CN112972058A CN 112972058 A CN112972058 A CN 112972058A CN 202110254986 A CN202110254986 A CN 202110254986A CN 112972058 A CN112972058 A CN 112972058A
- Authority
- CN
- China
- Prior art keywords
- rat
- cerebral hemorrhage
- rats
- establishing
- evaluating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 41
- 206010008111 Cerebral haemorrhage Diseases 0.000 title claims abstract description 32
- 238000010171 animal model Methods 0.000 claims abstract description 8
- 241000700159 Rattus Species 0.000 claims description 93
- 210000005013 brain tissue Anatomy 0.000 claims description 23
- 238000001514 detection method Methods 0.000 claims description 18
- 238000002474 experimental method Methods 0.000 claims description 15
- 210000003414 extremity Anatomy 0.000 claims description 14
- 210000004556 brain Anatomy 0.000 claims description 12
- 208000032843 Hemorrhage Diseases 0.000 claims description 11
- 230000000740 bleeding effect Effects 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 238000013077 scoring method Methods 0.000 claims description 9
- 230000009471 action Effects 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 241001481798 Stochomys longicaudatus Species 0.000 claims description 6
- 230000006399 behavior Effects 0.000 claims description 6
- 239000002961 echo contrast media Substances 0.000 claims description 6
- 238000010253 intravenous injection Methods 0.000 claims description 6
- 230000007971 neurological deficit Effects 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 6
- 238000010186 staining Methods 0.000 claims description 6
- 230000007547 defect Effects 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 238000010968 computed tomography angiography Methods 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 claims description 4
- 238000003384 imaging method Methods 0.000 claims description 4
- 238000001262 western blot Methods 0.000 claims description 4
- 206010059491 Intracranial haematoma Diseases 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 230000008499 blood brain barrier function Effects 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 3
- 230000036760 body temperature Effects 0.000 claims description 3
- 210000002683 foot Anatomy 0.000 claims description 3
- 210000004744 fore-foot Anatomy 0.000 claims description 3
- 230000005021 gait Effects 0.000 claims description 3
- 230000003862 health status Effects 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 230000003188 neurobehavioral effect Effects 0.000 claims description 3
- 230000007658 neurological function Effects 0.000 claims description 3
- 210000002637 putamen Anatomy 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 3
- 230000003068 static effect Effects 0.000 claims description 3
- 230000002618 waking effect Effects 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 13
- 238000011156 evaluation Methods 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 11
- 108091007960 PI3Ks Proteins 0.000 abstract description 9
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 abstract description 9
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract description 9
- 102000004169 proteins and genes Human genes 0.000 abstract description 8
- 230000004900 autophagic degradation Effects 0.000 abstract description 4
- 230000019491 signal transduction Effects 0.000 abstract description 4
- 102100021251 Beclin-1 Human genes 0.000 abstract description 3
- 101000894649 Homo sapiens Beclin-1 Proteins 0.000 abstract description 3
- 230000002068 genetic effect Effects 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 abstract 1
- 102000038030 PI3Ks Human genes 0.000 description 8
- 108091008611 Protein Kinase B Proteins 0.000 description 8
- 238000001467 acupuncture Methods 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 4
- 210000001364 upper extremity Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000008116 Traumatic Cerebral Hemorrhage Diseases 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- -1 p-AKT Proteins 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K29/00—Other apparatus for animal husbandry
- A01K29/005—Monitoring or measuring activity, e.g. detecting heat or mating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D1/00—Surgical instruments for veterinary use
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Environmental Sciences (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明公开了一种大脑出血模型鼠的建立和评价方法,包括:A.准备工作;B.脑出血模型建立;C.生物模型评价;D.实验动物分组和检验;本发明根据前期的选筛和培育,减少实验流程中针对脑出血生物建模的影响,同时能够筛选受到脑出血遗传基因影响的大鼠,可直接跳过人为建模,进一步降低实验流程步骤,同时分别从蛋白和RNA水平,全面而深入的分析了PI3K/AKT/mTOR信号通路和自噬关键蛋白LC3‑B、BECN1的表达变化,能够针对生物脑出血具有更为详细的最终评价。
Description
技术领域
本发明涉及一种,特别涉及一种大脑出血模型鼠的建立和评价方法。
背景技术
脑出血作为脑卒中的一个亚型,是指非外伤性脑实质出血,具有发病率和死亡率高、预后差、并发症多等特点,对人体的危害仅次于恶性肿瘤和心脏疾病,是人类致死和致残的重要原因之一。脑出血后的病理损伤主要包括物理性损伤和血肿的占位效应等引起的原发性脑损伤,以及血液循环障碍、代谢紊乱、脑水肿、炎症反应和神经细胞死亡等继发性脑损伤,。
而现有的脑出血生物建模方式一般为胶原酶注入法、自体血局部注入法和高血压基因动物培育,均具有出血量不可控、出血区域不可控和自然性模拟受外力影响等问题,同时在后续所形成的评价方式不够准确,对照实验中组别较多和对照实验的结论难以确认等现象。
发明内容
本发明要解决的技术问题是克服现有技术的缺陷,提供一种大脑出血模型鼠的建立和评价方法。
为了解决上述技术问题,本发明提供了如下的技术方案:
本发明一种大脑出血模型鼠的建立和评价方法,具体包括如下步骤:
A.准备工作;
选取SPF级大鼠,月龄均为3-9个月,体重为250-500g,按照大鼠脑立体定位图谱确定大鼠右侧尾壳核部位,对大鼠颅顶目标区域脱毛,将麻醉后备皮的大鼠固定于立体定位仪上;
B.脑出血模型建立;
采用超声造影剂对目标大鼠静脉注射,并结合超声设备,利用超声探头于大鼠颅顶目标区域覆盖,利用超声造影剂形成血脑屏障开放,血液由血管内部向脑实质渗出;
C.生物模型评价;
针对苏醒后的大鼠,按照其动作和行为评分,同时采用CT血管造影成像详细检查出血区域;
D.实验动物分组和检验;
将实验动物按照模型对照组、实验组、3-MA抑制剂组和3-MA抑制剂式实验组分类,实验完成后即采用神经行为观测、染色检测和脑组织检测法,验证最终实验结果。
作为本发明的一种优选技术方案,所述步骤C中,大鼠造模后平均苏醒时间约为2小时,后将大鼠放置于无盖木质空箱子内,观察其前爪形态及行走步态等体征,针对动作和行为的评分标准如下:
(1)大鼠与造模前并无异样,可正常自由行走,即为无神经功能缺损,计0分;
(2)大鼠病灶对侧前爪于行走或静态时不能完全伸展,计1分;
(3)大鼠行走时向病灶对侧转圈或行走轨迹呈弧线状,计2分;
(4)大鼠行走时肢体向病灶对侧倾斜或倾倒,计3分;
(5)大鼠苏醒后,有肢体活动但不能自发行走或有意识丧失等症状,计4分;
上述评分标准中>0者判定为出现神经功能缺损体征,在步骤D中处死后取脑证实颅内血肿者视为造模成功,否则弃之不用,在同批大鼠中随机抽样重新入组。
作为本发明的一种优选技术方案,所述步骤D中的检验方法具体包括如下步骤:
神经行为学观察方法中,主要应用Berderson评分法,同时参考Longa肢体对称实验评分法;
染色检测法主要为HE染色检测脑组织病变法;
脑组织检测法中包含有ELISA检测脑组织和Westernblot法检测脑组织。
作为本发明的一种优选技术方案,所述步骤A中,大鼠需于实验前1周内饲养观察健康状态,具有遗传性脑出血的大鼠筛出并跳过步骤B,具有影响神经类疾病的大鼠筛出弃用。
作为本发明的一种优选技术方案,所述步骤B中,需保持目标大鼠的体温维持至35-36度,静脉注射区域为大鼠尾部,同时在注射后10-15s后将其尾部置于45-50度水中浸泡。
与现有技术相比,本发明的有益效果如下:
1:本发明通过采用超声造影方式,减少后续评价和检验流程中的组别对照,并且设置相应的环境温度和水温影响大鼠的体液代谢速度,增加超声造影生物模型制作效率。
2:本发明根据前期的选筛和培育,减少实验流程中针对脑出血生物建模的影响,同时能够筛选受到脑出血遗传基因影响的大鼠,可直接跳过人为建模,进一步降低实验流程步骤。
3:本发明运用免疫印迹分析和WB技术,分别从蛋白和RNA水平,全面而深入的分析了PI3K/AKT/mTOR信号通路和自噬关键蛋白LC3-B、BECN1的表达变化,能够针对生物脑出血具有更为详细的最终评价。
附图说明
附图用来提供对本发明的进一步理解,并且构成说明书的一部分,与本发明的实施例一起用于解释本发明,并不构成对本发明的限制。在附图中:
图1是本发明的评价流程示意图;
具体实施方式
以下本发明的优选实施例进行说明,应当理解,此处所描述的优选实施例仅用于说明和解释本发明,并不用于限定本发明。
实施例1
本发明提供一种大脑出血模型鼠的建立和评价方法,具体包括如下步骤:
A.准备工作;
选取SPF级大鼠,月龄均为3-9个月,体重为250-500g,按照大鼠脑立体定位图谱确定大鼠右侧尾壳核部位,对大鼠颅顶目标区域脱毛,将麻醉后备皮的大鼠固定于立体定位仪上;
B.脑出血模型建立;
采用超声造影剂对目标大鼠静脉注射,并结合超声设备,利用超声探头于大鼠颅顶目标区域覆盖,利用超声造影剂形成血脑屏障开放,血液由血管内部向脑实质渗出;
C.生物模型评价;
针对苏醒后的大鼠,按照其动作和行为评分,同时采用CT血管造影成像详细检查出血区域;
其CT血管造影成像所形成的出血范围主要为下表所示:
根据上表将大鼠出血范围进行记录和标记,随后按照下一步骤中的神经功能评分,结合其出血部位进一步评价出血范围的多少、出血量的多少形成辅助性评价,用以针对后续实验组的数据收集和记录,方便形成完整且详细的评价流程。
D.实验动物分组和检验;
将实验动物按照模型对照组、实验组、3-MA抑制剂组和3-MA抑制剂式实验组分类,实验完成后即采用神经行为观测、染色检测和脑组织检测法,验证最终实验结果;
上述组别中,每组24只,再将各组随机分为4个时间亚组,即造模后6h、24h、72h和7d,每亚组6只,无需空白组,本次实验流程设计为针灸实验,分析在“针灸”状态下,脑出血组织中“磷脂酰肌醇3激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白(PI3K/AKT/mTOR)”指标变化,并分析:针刺抑制磷脂酰肌醇3激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白的表达;
实验组于造模后6小时开始以毫针由患侧百会穴透刺曲鬓穴,每24小时针刺一次,参照《实验动物穴位图谱》取穴,进针1.5cm,留针30min,每5min捻转1次,每次5min;3-MA抑制剂组在造模前15分钟于前囟点右1.5mm,后0.8mm定位钻孔注射抑制剂3-MA(400nm);3-MA抑制剂式实验组于注射抑制剂和建模后,给予与针刺组相同的针刺方法进行干预。
步骤C中,大鼠造模后平均苏醒时间约为2小时,后将大鼠放置于无盖木质空箱子内,观察其前爪形态及行走步态等体征,针对动作和行为的评分标准如下:
(1)大鼠与造模前并无异样,可正常自由行走,即为无神经功能缺损,计0分;
(2)大鼠病灶对侧前爪于行走或静态时不能完全伸展,计1分;
(3)大鼠行走时向病灶对侧转圈或行走轨迹呈弧线状,计2分;
(4)大鼠行走时肢体向病灶对侧倾斜或倾倒,计3分;
(5)大鼠苏醒后,有肢体活动但不能自发行走或有意识丧失等症状,计4分;
上述评分标准中>0者判定为出现神经功能缺损体征,在步骤D中处死后取脑证实颅内血肿者视为造模成功,否则弃之不用,在同批大鼠中随机抽样重新入组。
步骤D中的检验方法具体包括如下步骤:
神经行为学观察方法中,主要应用Berderson评分法,同时参考Longa肢体对称实验评分法;
Berderson评分法,同时参考Longa肢体对称实验评分法在于术后6h、1d、3d、7d综合评价神经功能缺损症状和体征,肢体对称试验评分法是将大鼠放网眼大小为2-3厘米的网里,在其行走时,计数2分钟内其前肢漏到网眼中的次数;
Berderson神经功能缺损体征评分法:0分为轻抓大鼠尾端,抬起高于桌面至20cm,观察大鼠四肢活动情况;1分为可向地面伸展双上肢并无其它神经缺陷,病灶对侧肢体(左侧)出现肘、腕关节屈曲及肩关节内收体征;2分为将大鼠放于鼠爪可抓牢的塑料压膜纸垫上,固定鼠尾,缓慢在其肩后给予侧压至前肢滑动3cm,每侧肢体各向左侧推或向右侧推10次,多次出现左侧抵抗力下降;3分为大鼠自由活动时出现向患侧转圈体征,如追尾征;
Longa评分法:0分为无神经功能缺损症状;1分为左侧前肢完全伸展不能;2分为大鼠向左侧转圈;3分为瘫痪侧倾倒;4分为可有意识丧失不能行走;
染色检测法主要为HE染色检测脑组织病变法:在各组大鼠出血24h后,于冰上快速断头处死大鼠,在冰盘上取出部分脑组织,用100g/L甲醛固定24h,梯度乙醇脱水,二甲苯透明后进行石蜡包埋,制成石蜡切片;冠状切片,片厚4μm,进行HE染色观察病变情况;
脑组织检测法中包含有ELISA检测脑组织和Westernblot法检测脑组织;
ELISA检测脑组织IL-10、IL-1β和TNF-α的含量:各组大鼠脑出血24h后,快速断头处死大鼠,取出部分脑组织剪碎后加入生理盐水,在匀浆器中混匀搅碎;将获得的脑组织匀浆在4℃下6000r/min离心15min,取上清液,按照ELISA试剂盒说明书检测脑组织中IL-10、IL-1β和TNF-α的含量;
Westernblot法检测脑组织PI3K、AKT、p-AKT、mTOR、p-mTOR蛋白水平:各取100mg左右保存于-80℃的各组脑组织,采用RIPA裂解液提取各组脑组织的蛋白质;采用BCA法测定蛋白浓度,采用120g/L的SDS-PAGE分离后,转印至PVDF膜上。使用50g/L脱脂奶粉室温封闭1h,经TBST洗涤后,加入兔抗人PI3K单克隆抗体(1∶2000)、兔抗人AKT多克隆抗体(1∶500)、兔抗人p-AKT多克隆抗体(1∶1000)、兔抗人mTOR多克隆抗体(1∶2000)、兔抗人p-mTOR多克隆抗体(1∶400)、兔抗人β-actin多克隆抗(1∶2000),4℃孵育过夜;TBST再次洗涤后,加入HPR标记的山羊抗兔IgG(1∶2000),室温孵育1h;洗膜,ECL化学发光试剂对其曝光显影,拍照保存。
所形成的实验流程和评价结果而言,从生物建模中加强实验效率,通过采用声波设备控制脑出血,从而减少无必要的空白对照组,例如本实施例1中的针灸实验,降低了实验复杂程度,随后按照动物水平中的流程评价,根据神经功能评分、机制指标和代谢指标,形成最终的完整性观测和评价方法,并依旧能够达到观察PI3K/AKT/mTOR信号通路与脑出血模型中神经细胞自噬的关系,以及阐明“针灸”是如何保护脑出血神经功能及作用机制,同时能够采用免疫印迹分析和WB技术,分别从蛋白和RNA水平,全面而深入的分析了PI3K/AKT/mTOR信号通路和自噬关键蛋白LC3-B、BECN1的表达变化,为针刺治疗脑出血提供了有力的理论依据。
实施例2
步骤A中,大鼠需于实验前1周内饲养观察健康状态,具有遗传性脑出血的大鼠筛出并跳过步骤B,具有影响神经类疾病的大鼠筛出弃用,其它步骤与实施例1相同。
使通过筛选后的大鼠,可根据实验需求进一步简化实验流程,增加生物建模流程中的效率,特别是在筛选出已具有脑出血遗传的大鼠时,其实验流程则可从线性流程成为并列式流程,步骤B可与步骤C同时实时。
实施例3
步骤B中,需保持目标大鼠的体温维持至35-36度,静脉注射区域为大鼠尾部,同时在注射后10-15s后将其尾部置于45-50度水中浸泡,其它步骤与实施例2相同。
使注射后的尾部在止血愈合后,即可通过温水浸泡增加大鼠的体液代谢速度,小幅度增加实验进度。
最后应说明的是:以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (5)
1.一种大脑出血模型鼠的建立和评价方法,其特征在于,具体包括如下步骤:
A.准备工作;
选取SPF级大鼠,月龄均为3-9个月,体重为250-500g,按照大鼠脑立体定位图谱确定大鼠右侧尾壳核部位,对大鼠颅顶目标区域脱毛,将麻醉后备皮的大鼠固定于立体定位仪上;
B.脑出血模型建立;
采用超声造影剂对目标大鼠静脉注射,并结合超声设备,利用超声探头于大鼠颅顶目标区域覆盖,利用超声造影剂形成血脑屏障开放,血液由血管内部向脑实质渗出;
C.生物模型评价;
针对苏醒后的大鼠,按照其动作和行为评分,同时采用CT血管造影成像详细检查出血区域;
D.实验动物分组和检验;
将实验动物按照模型对照组、实验组、3-MA抑制剂组和3-MA抑制剂式实验组分类,实验完成后即采用神经行为观测、染色检测和脑组织检测法,验证最终实验结果。
2.根据权利要求1所述的一种大脑出血模型鼠的建立和评价方法,其特征在于,所述步骤C中,大鼠造模后平均苏醒时间约为2小时,后将大鼠放置于无盖木质空箱子内,观察其前爪形态及行走步态等体征,针对动作和行为的评分标准如下:
(1)大鼠与造模前并无异样,可正常自由行走,即为无神经功能缺损,计0分;
(2)大鼠病灶对侧前爪于行走或静态时不能完全伸展,计1分;
(3)大鼠行走时向病灶对侧转圈或行走轨迹呈弧线状,计2分;
(4)大鼠行走时肢体向病灶对侧倾斜或倾倒,计3分;
(5)大鼠苏醒后,有肢体活动但不能自发行走或有意识丧失等症状,计4分;
上述评分标准中>0者判定为出现神经功能缺损体征,在步骤D中处死后取脑证实颅内血肿者视为造模成功,否则弃之不用,在同批大鼠中随机抽样重新入组。
3.根据权利要求1所述的一种大脑出血模型鼠的建立和评价方法,其特征在于,所述步骤D中的检验方法具体包括如下步骤:
神经行为学观察方法中,主要应用Berderson评分法,同时参考Longa肢体对称实验评分法;
染色检测法主要为HE染色检测脑组织病变法;
脑组织检测法中包含有ELISA检测脑组织和Westernblot法检测脑组织。
4.根据权利要求1所述的一种大脑出血模型鼠的建立和评价方法,其特征在于,所述步骤A中,大鼠需于实验前1周内饲养观察健康状态,具有遗传性脑出血的大鼠筛出并跳过步骤B,具有影响神经类疾病的大鼠筛出弃用。
5.根据权利要求1所述的一种大脑出血模型鼠的建立和评价方法,其特征在于,所述步骤B中,需保持目标大鼠的体温维持至35-36度,静脉注射区域为大鼠尾部,同时在注射后10-15s后将其尾部置于45-50度水中浸泡。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110254986.5A CN112972058A (zh) | 2021-03-09 | 2021-03-09 | 一种大脑出血模型鼠的建立和评价方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110254986.5A CN112972058A (zh) | 2021-03-09 | 2021-03-09 | 一种大脑出血模型鼠的建立和评价方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112972058A true CN112972058A (zh) | 2021-06-18 |
Family
ID=76336099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110254986.5A Withdrawn CN112972058A (zh) | 2021-03-09 | 2021-03-09 | 一种大脑出血模型鼠的建立和评价方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112972058A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114568385A (zh) * | 2022-02-15 | 2022-06-03 | 承德医学院 | 软体性自体血微栓子制备多发性脑梗死造模装置和方法 |
-
2021
- 2021-03-09 CN CN202110254986.5A patent/CN112972058A/zh not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114568385A (zh) * | 2022-02-15 | 2022-06-03 | 承德医学院 | 软体性自体血微栓子制备多发性脑梗死造模装置和方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Das | Neural transplantation in mammalian brain: some conceptual and technical considerations | |
CN111149767B (zh) | 一种人源化皮肤型红斑狼疮小鼠模型的构建方法和应用 | |
CN116173112B (zh) | 中药配方益生菌组合物及制备方法和在改善男性性功能中的应用 | |
Peruzzaro et al. | The impact of enriched environment and transplantation of murine cortical embryonic stem cells on recovery from controlled cortical contusion injury | |
US20130078221A1 (en) | Multipotent adult stem cell derived from canine umbilical cord blood, placenta and canine fetus heart, method for preparing the same and cellular therapeutics containing the same | |
Garvican et al. | Exposure of a tendon extracellular matrix to synovial fluid triggers endogenous and engrafted cell death: a mechanism for failed healing of intrathecal tendon injuries | |
CN112972058A (zh) | 一种大脑出血模型鼠的建立和评价方法 | |
Harris | The corpus callosum and hemispheric communication: An historical survey of theory and research | |
Senn | The pathology and surgical treatment of tumors | |
Ghasemi et al. | Filarial worms: a systematic review and meta-analysis of diversity in animals from Iran with emphasis on human cases | |
Roballo et al. | Long‐term neural regeneration following injury to the peroneal branch of the sciatic nerve in sheep | |
Warren | The physiological effects of roentgen radiation upon normal body tissues | |
Kelp et al. | Establishing and monitoring of urethral sphincter deficiency in a large animal model | |
CN107320717A (zh) | 催乳素在治疗椎间盘退变过程中的应用 | |
CN106236318A (zh) | 泡球蚴经肝门静脉途径感染肝脏的泡型包虫病动物模型的构建方法 | |
CN116814540A (zh) | 一种微电场诱导的干细胞来源小细胞外囊泡及其制备方法和应用 | |
Kim et al. | Comparison of sensory recovery and morphologic change between sensate and nonsensate flaps in oral cavity and oropharyngeal reconstruction | |
Chen et al. | Stereotaxic atlas of the infant rat brain at postnatal days 7–13 | |
Jia et al. | Modeling distal middle cerebral artery occlusion in neonatal rodents with magnetic nanoparticles or magnetized red blood cells | |
Matkuliev et al. | Myringoplasty with application xenograft from sheep pericardia | |
Grigonis et al. | Visual callosal projections in the adult ferret | |
Cornet | Tuberculosis and acute general miliary tuberculosis | |
CN114948320A (zh) | 一种简便的慢性硬膜下血肿动物造模方法 | |
Bala et al. | A Pre Experimental Study to Assess the Effectiveness of STP on Knowledge Regarding Umbilical Cord Blood Banking among Nursing Students at Selected Areas in Jammu | |
Wai | The Anatomical Distribution of Mechanoreceptors across the Hind Paw of Integrin a1-null and Wild Type Mice using Serial Histological Sectioning |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210618 |
|
WW01 | Invention patent application withdrawn after publication |